BioSpace News Archive

Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced that Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, will present at the following upcoming virtual conferences. Event H.C. Wainwright Global Life Sciences Conference Date March 9-10, 2021

MedMira Inc. announces the expansion of its product portfolio and outlines the company’s COVID-19 market and regulatory plan.

MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that management will be participating in the following virtual investor conferences: H.C. Wainwright Global Life Sciences Conference Presentation: Wednesday, March 10, 2021 available to view on-demand beginning at 2:00 PM ET

~ Submitted New Drug Application (NDA) for RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome to U.S. Food & Drug Administration ~ ~ KEVEYIS® (dichlorphenamide) Full-Year 2020 Revenue of $30.7 Million, a 41.5 Percent Increase over 2019 Revenue of $21.7 Million ~ ~ Full-Year 2021 KEVEYIS ® (dichlorphenamide) Revenue Guidance of $34 Million to $36 Million ~ ~ Company Reports $87.5 Million in Cash on Hand;

89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will participate in the virtual H.C. Wainwright Global Life Sciences Conference to be held March 9-10, 2021.

Cognition Therapeutics, Inc. , a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, reported that Lisa Ricciardi and James O’Brien , Cognition’s chief executive and chief financial officers, would be making a company presentation at the annual H.C. Wainwright Global Life Sciences Conference.

CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced that members of its senior management team are scheduled to participate in the following virtual investor conferences in March:

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that Algernon’s CEO Christopher J. Moreau and DMT Consultant Dr. David Nutt DM, FRCP, FRCPSYCH, FSB, FMEDSCI will be discussing the Company’s DMT Stroke Clinical Research Program on an upcoming BioPub webcast.

BetterLife Pharma Inc., an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders and viral infections, announces it has entered into an agreement with Eurofins CDMO Alphora Inc. for TD-0148A’s GMP manufacturing.

Arbor Biotechnologies announced today the appointment of Mark D. Angelino, co-founder and former Chief Operating Officer of Generation Bio, to its Board of Directors. Mark brings significant company building and product development experience to the Arbor Board, given his expertise over the past 20 years working with numerous leading pharmaceutical companies.